Literature DB >> 16291936

Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).

Martin Ramsden1, Linda Kotilinek, Colleen Forster, Jennifer Paulson, Eileen McGowan, Karen SantaCruz, Aaron Guimaraes, Mei Yue, Jada Lewis, George Carlson, Michael Hutton, Karen H Ashe.   

Abstract

Here, we describe the generation of a novel transgenic mouse model of human tauopathy. The rTg(tau(P301L))4510 mouse expresses the P301L mutation in tau (4R0N) associated with frontotemporal dementia and parkinsonism linked to chromosome 17. Transgene expression was driven by a forebrain-specific Ca(2+) calmodulin kinase II promoter system resulting in high levels of expression in the hippocampus and neocortex. Importantly, transgene expression in this model is induced via the tetracycline-operon responsive element and is suppressed after treatment with doxycycline. Continued transgene expression in rTg(tau(P301L))4510 mice results in age-dependent development of many salient characteristics of hereditary human dementia. From an early age, immunohistochemical studies demonstrated abnormal biochemical processing of tau and the presence of pathological conformation- and phosphorylation-dependent epitopes. Neurofibrillary tangle (NFT) pathology was first observed in the neocortex and progressed into the hippocampus and limbic structures with increasing age. Consistent with the formation of NFTs, immunoblots indicated an age-dependent transition of accumulating tau species from Sarkosyl soluble 55 kDa to insoluble hyperphosphorylated 64 kDa. Ultrastructural analysis revealed the presence of straight tau filaments. Furthermore, the effects of tau(P301L) expression on spatial reference memory were longitudinally tested using the Morris water maze. Compared with nontransgenic age-matched control littermates, rTg(tau(P301L))4510 mice developed significant cognitive impairments from 4 months of age. Memory deficits were accompanied by gross forebrain atrophy and a prominent loss of neurons, most strikingly in hippocampal subdivision CA1. Collectively, these data describe a novel transgenic mouse that closely mimics human tauopathy and may represent an important model for the future study of tau-related neurodegenerative disease.

Entities:  

Mesh:

Year:  2005        PMID: 16291936      PMCID: PMC6725849          DOI: 10.1523/JNEUROSCI.3279-05.2005

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  280 in total

1.  Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss.

Authors:  Tetsuya Kimura; Tetsuya Fukuda; Naruhiko Sahara; Shunji Yamashita; Miyuki Murayama; Tatsuya Mizoroki; Yuji Yoshiike; Boyoung Lee; Ioannis Sotiropoulos; Sumihiro Maeda; Akihiko Takashima
Journal:  J Biol Chem       Date:  2010-10-04       Impact factor: 5.157

2.  Humanin attenuates Alzheimer-like cognitive deficits and pathological changes induced by amyloid β-peptide in rats.

Authors:  Gao-Shang Chai; Dong-Xiao Duan; Rong-Hong Ma; Jian-Ying Shen; Hong-Lian Li; Zhi-Wei Ma; Yu Luo; Lu Wang; Xin-Hua Qi; Qun Wang; Jian-Zhi Wang; Zelan Wei; Darrell D Mousseau; Li Wang; Gongping Liu
Journal:  Neurosci Bull       Date:  2014-11-12       Impact factor: 5.203

3.  Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer's disease.

Authors:  Charles Y Shao; Suzanne S Mirra; Hameetha B R Sait; Todd C Sacktor; Einar M Sigurdsson
Journal:  Acta Neuropathol       Date:  2011-06-01       Impact factor: 17.088

4.  Neurogenesis in Alzheimer´s disease: a realistic alternative to neuronal degeneration?

Authors:  Rocío E Gonzalez-Castaneda; Alma Y Galvez-Contreras; Sonia Luquín; Oscar Gonzalez-Perez
Journal:  Curr Signal Transduct Ther       Date:  2011-09-01

5.  Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.

Authors:  Donna M Barten; Patrizia Fanara; Cathy Andorfer; Nina Hoque; P Y Anne Wong; Kristofor H Husted; Gregory W Cadelina; Lynn B Decarr; Ling Yang; Victoria Liu; Chancy Fessler; Joan Protassio; Timothy Riff; Holly Turner; Christopher G Janus; Sethu Sankaranarayanan; Craig Polson; Jere E Meredith; Gemma Gray; Amanda Hanna; Richard E Olson; Soong-Hoon Kim; Gregory D Vite; Francis Y Lee; Charles F Albright
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

6.  Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration.

Authors:  Brian R Hoover; Miranda N Reed; Jianjun Su; Rachel D Penrod; Linda A Kotilinek; Marianne K Grant; Rose Pitstick; George A Carlson; Lorene M Lanier; Li-Lian Yuan; Karen H Ashe; Dezhi Liao
Journal:  Neuron       Date:  2010-12-22       Impact factor: 17.173

7.  Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models.

Authors:  Holly C Hunsberger; Sharay E Setti; Ryan T Heslin; Jorge E Quintero; Greg A Gerhardt; Miranda N Reed
Journal:  J Vis Exp       Date:  2017-05-03       Impact factor: 1.355

8.  Quantitative measurement of postural sway in mouse models of human neurodegenerative disease.

Authors:  D Hutchinson; V Ho; M Dodd; H N Dawson; A C Zumwalt; D Schmitt; C A Colton
Journal:  Neuroscience       Date:  2007-07-21       Impact factor: 3.590

9.  Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy.

Authors:  Tara L Spires; Jennifer D Orne; Karen SantaCruz; Rose Pitstick; George A Carlson; Karen H Ashe; Bradley T Hyman
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

10.  Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy.

Authors:  Chad Dickey; Clara Kraft; Umesh Jinwal; John Koren; Amelia Johnson; Laura Anderson; Lori Lebson; Daniel Lee; Dennis Dickson; Rohan de Silva; Lester I Binder; David Morgan; Jada Lewis
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.